Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-09-12
1999-10-19
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540520, C07D48706, A61K 3155
Patent
active
059689277
ABSTRACT:
This invention is directed to novel tricyclic ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions of such tricyclic compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, and for the prevention of ischemic injury.
REFERENCES:
patent: 5504080 (1996-04-01), Karanewsky
patent: 5604408 (1997-02-01), Karanewsky et al.
Baringa, M., "Cell Death Studies Yield Cancer Clues", Science, 259:760-762 (1993).
De Lombaert et al., "Practical Synthesis of a Novel Tricyclic Dipeptide Mimetic Based on [6H]-Azepino Indoline Nucleus: Application to Angiotensin-Converting Enzyme Inhibition", Tetrahedron Letters, 35:7513-7516 (1994).
Gagliardini et al., "Prevention of Vertebrate Neuronal Death by the crmA Gene ", Science, 263:826-828 (1994).
Howard et al., "IL-1-Converting Enzyme Requires Aspartic Acid Residues for Processing of the I1-1.beta. Precursor at two Distinct Site and Does Not Cleave 31-kDa I1-1.alpha.", J. Immunol., 147:2964-2969 (1991).
Jones, "Amino Acid and Peptide Synthesis," Steven G. Davis ed., Oxford University Press, Oxford, pp. 25-41 (1992).
Lonnemann, et al., "Difference in the Synthesis and Kinetics of Release of Interleukin 1.alpha., interleukin 1.beta. and tumor necrosis factor from human mononuclear cells", Eur. J. Immunol., 19:1531-1536 (1989).
Miura, M. et al., "Induction of Apoptosis in Fibroblasts by IL-1.beta.-Converting Enzyme, a Mammalian Homolog for the C. elegans Cell Death Gene ced-3", Cell, 75:653-660 (1993).
Mosely, et al., "Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1.alpha. and 1.beta.", Proc. Nat. Acad. Sci., 84:4572-4576 (1987).
Nett-Fiordalisi, et al., "Macrophage Apoptosis in the Absence of Active Interleukin-1.beta.-Converting Enzyme", Journal of Leukocyte Biology, 58:717-724 (1995).
Nicholson et al., "Identification and Inhibition of the ICE/CED-3 Protease necessary for Mammalian Apoptosis", Nature, 376:37-43 (1995).
Oppenheim, et al., "There is more than one Interleukin 1", Immunology Today, 7:45-56 (1986).
Plattner, J.J. and D.W. Norbeck, in Drug Discovery Technologies, C.R. Clark and W.H. Moos, Eds. (Ellis Horwood, Chichester, England, 1990), pp. 92-126.
Robl et al., "Synthesis of Benzo-Fused, 7,5-and 7,6-Fused Azepinones as Conformationally Restricted Dipeptide Mimetics", Tetrahedron Letters, 36:1593-1596 (1995).
Sleath et al., "Substrate Specificity of the Protease That Processes Human Interleukin-1.beta.", J. Biol. Chem., 265:14526-14528 (1992).
Thornberry et al., "A Novel Heterodimeric Cysteine Protease is Required for Interleukin-1.beta. Processing in Monocytes", Nature, 356:768:774 (1992).
Yuan et al., "The C. elegans Cell Death Gene ced-3 Encodes a Protein Similar to Mammalian Interleukin-1.beta.-Converting Enzyme", Cell, 75:641-652 (1993).
Karanewsky Donald S.
Linton Steven D.
Idun Pharmaceuticals, Inc.
Kifle Bruck
Raymond Richard L.
LandOfFree
Tricyclic compounds for the inhibition of the ICE/ced-3 protease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic compounds for the inhibition of the ICE/ced-3 protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic compounds for the inhibition of the ICE/ced-3 protease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2055563